ClinicalTrials.gg
CompletedNCT01703286Updated Jan 19, 2015Results posted

Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

A Phase 1 interventional study of Placebo and Linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-01-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
51st of 67
42 · median 175
Started
2012
with 5 others
Phase 1
7 of 67
none open now
Registered
30th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 51st largest by enrollment, is one of 6 that started in 2012, is one of 7 in phase 1, and was the 30th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus. In the current trial this effect of linagliptin treatment on endothelial function will be compared against both the sulfonylurea glimepiride and against placebo, which has not been tested in a trial before; as also is the case for other DPP-4 inhibitors.

Besides placebo, glimepiride was chosen as a comparator, as it is one compound of the second most used oral antidiabetic drug class.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Type 2 diabetic male and female patients according to the following criteria:

    Based upon a complete medical history and clinical laboratory tests

  2. Age >= 18 and Age \<= 65 years
  3. >= 25 \<= 35 kg/m2
  4. \<= 7.5%
  5. Treatment with metformin (=1500 mg daily) for \<= 3 months
  6. Signed and dated written prior to admission to the study in accordance with GCP and the local legislation.

    For female patients of :

  7. Use of acceptable method of (Pearl-Index \<1).

Exclusion criteria

Exclusion criteria:

  1. Treatment with any glucose-lowering drug except for metformin within prior 3 months.
  2. Any finding of the medical examination (including blood pressure, pulse rate and ) deviating from normal and of clinical relevance.
  3. Any evidence of a acute concomitant disease
  4. History of cardiovascular disease (e.g. coronary artery disease history of acute myocard infarction or stroke, peripheral vascular disease).
  5. History of major diabetic complications (e.g. nephropathy, retinopathy)
  6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, immunological or hormonal disorders (except: hypertension treated with angiotensin receptor blocker or angiotensin-converting-enzyme inhibitors, hyperlipidemia with statin therapy, thyroid hormone replacement therapy, all stable for at least three months prior to screening).
  7. Surgery of the gastrointestinal tract (except appendectomy).
  8. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
  9. History of relevant orthostatic hypotension, fainting spells or blackouts.
  10. Chronic or relevant acute infections.
  11. History of relevant allergy/ (including allergy to drug or its ).
  12. Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial.
  13. Participation in another trial with an drug within one month prior to administration or during the trial.
  14. Smoker (>= 1 cigarettes or >= 1 cigars or >= 1 pipes/day).
  15. Alcohol abuse (more than 60 g/day).
  16. Drug abuse.
  17. Blood donation (more than 100 mL within four weeks prior to administration or during the trial).
  18. Excessive physical activities (within one week prior to administration or during the trial).
  19. Any laboratory value outside the reference range that is of clinical relevance.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Linagliptin 5mg

    given once daily over 28 days

    Drug: Placebo · Drug: Linagliptin

  • Active comparator
    Glimepiride

    given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days

    Drug: Placebo · Drug: Glimepiride

  • Placebo comparator
    Placebo

    given once daily over 28 days

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo matching Glimepiride

  • given once daily for 28 days

  • DrugPlacebo

    Placebo matching Linagliptin

  • DrugPlacebo

    Placebo matching Linagliptin

  • DrugPlacebo

    Placebo matching Glimepiride

  • 1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28

    Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.

    Time frame: baseline and day 28 for each treatment arm

Secondary outcomes

  1. Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28

    Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.

    Time frame: baseline and day 28 for each treatment arm

  2. Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28

    Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.

    Time frame: baseline and day 28 for each treatment arm

  3. Number of Patients With Adverse Events

    Number of patients with any adverse events

    Time frame: up to 20 weeks

07

Results

Posted Jan 19, 2015

Participant flow

Period 1 Including Washout
Participant flow — Period 1 Including Washout
MilestonePbo/ G1-4/ L 5L 5/ G 1-4/ PboG 1-4/ L 5/ PboG1-4/ Pbo/ L 5Pbo/ L 5/ G1-4L 5/ Pbo/ G1-4/
Started777777
Completed777676
Not completed000101
Withdrew: Withdrawal by subject000101
Period 2 Including Washout
Participant flow — Period 2 Including Washout
MilestonePbo/ G1-4/ L 5L 5/ G 1-4/ PboG 1-4/ L 5/ PboG1-4/ Pbo/ L 5Pbo/ L 5/ G1-4L 5/ Pbo/ G1-4/
Started777676
Completed777576
Not completed000100
Withdrew: Adverse event000100
Period 3 Including Washout
Participant flow — Period 3 Including Washout
MilestonePbo/ G1-4/ L 5L 5/ G 1-4/ PboG 1-4/ L 5/ PboG1-4/ Pbo/ L 5Pbo/ L 5/ G1-4L 5/ Pbo/ G1-4/
Started777576
Completed777576
Not completed000000

Outcome measures

PrimaryChange From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28

Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.

Time frame:
baseline and day 28 for each treatment arm
Reported as:
Geometric mean · percentage
Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28
percentageLinagliptin 5 mgGlimepiride 1-4 mgPlacebo
Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 280.885 (0.695 to 1.128)1.002 (0.795 to 1.262)1.002 (0.786 to 1.277)
Statistical analysis
  • Linagliptin 5 mg vs Glimepiride 1-4 mg · ANOVA · p = 0.5403 · Geometric mean ratio (net): 0.884 · 90% CI 0.633 to 1.235
  • Linagliptin 5 mg vs Placebo · ANOVA · p = 0.5402 · Geometric mean ratio (net): 0.884 · 90% CI 0.632 to 1.235
  • Glimepiride 1-4 mg vs Placebo · ANOVA · p = 0.9989 · Geometric mean ratio (net): 1.000 · 90% CI 0.715 to 1.397
SecondaryChange From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28

Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.

Time frame:
baseline and day 28 for each treatment arm
Reported as:
Geometric mean · Percentage
Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28
PercentageLinagliptin 5 mgGlimepiride 1-4 mgPlacebo
Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 281.262 (0.968 to 1.646)1.045 (0.815 to 1.339)1.009 (0.777 to 1.311)
Statistical analysis
  • Linagliptin 5 mg vs Glimepiride 1-4 mg · ANOVA · p = 0.3885 · Geometric mean ratio (net): 1.208 · 90% CI 0.840 to 1.738
  • Linagliptin 5 mg vs Placebo · ANOVA · p = 0.3105 · Geometric mean ratio (net): 1.251 · 90% CI 0.868 to 1.801
  • Glimepiride 1-4 mg vs Placebo · ANOVA · p = 0.8749 · Geometric mean ratio (net): 1.035 · 90% CI 0.721 to 1.485
SecondaryChange From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28

Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.

Time frame:
baseline and day 28 for each treatment arm
Reported as:
Mean · percentage
Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28
percentageLinagliptin 5 mgGlimepiride 1-4 mgPlacebo
Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 281.003 (0.945 to 1.061)1.053 (0.998 to 1.108)0.981 (0.923 to 1.039)
Statistical analysis
  • Linagliptin 5 mg vs Glimepiride 1-4 mg · ANOVA · p = 0.2982 · Mean difference (net): -0.050 · 90% CI -0.130 to 0.030
  • Linagliptin 5 mg vs Placebo · ANOVA · p = 0.6601 · Mean difference (net): 0.021 · 90% CI -0.059 to 0.101
  • Glimepiride 1-4 mg vs Placebo · ANOVA · p = 0.1412 · Mean difference (net): 0.072 · 90% CI -0.009 to 0.152
SecondaryNumber of Patients With Adverse Events

Number of patients with any adverse events

Time frame:
up to 20 weeks
Reported as:
Number · participants
Number of Patients With Adverse Events
participantsLinagliptin 5 mgGlimepiride 1-4 mgPlaceboREP - Linagliptin 5 mgREP - Glimepiride 1-4 mgRep - Placebo
Number of Patients With Adverse Events112514477

Adverse events

Collected over 28 days treatment period + 7 days residual effect period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Linagliptin 5 mg—0/40 (0%)6/40 (15%)
Glimepiride 1-4 mg—0/41 (0%)20/41 (48.8%)
Placebo—0/40 (0%)9/40 (22.5%)
Most frequent other events
Most frequent other events
EventLinagliptin 5 mgGlimepiride 1-4 mgPlacebo
HypoglycaemiaMetabolism and nutrition disorders2/4016/411/40
HeadacheNervous system disorders4/403/416/40
NasopharyngitisInfections and infestations1/406/413/40
HyperhidrosisSkin and subcutaneous tissue disorders0/403/410/40

Baseline characteristics

TS (treated set) - included all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial drug.

Age, Continuous
Age, Continuous(years)Total Participants
Mean60.3 ± 6.0
Sex: Female, Male
Sex: Female, Male(Participants)Total Participants
Female14
Male28
08

Study locations

1 site
  • 1218.105.001 Boehringer Ingelheim Investigational Site
    Neuss, Germany
09

References and documents

Publications

  • Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol. 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3. PubMed 28109295 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2012
First posted
Oct 10, 2012
Start
Oct 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Jan 19, 2015
Last update
Jan 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01703286
Responsible party
Sponsor
First posted
Oct 10, 2012
Start date
Oct 2012
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Jan 19, 2015
Last update
Jan 19, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion